Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
iOMEDICO AG, Freiburg, Germany
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provision of written informed consent (patient consent should be within 6 weeks of disease progression, defined elsewhere as the Index Date)
Adult male or female subjects (according to age of majority/adulthood as defined by local regulations)
Patients with prior confirmed EGFR mutation-positive (all mutations) locally advanced or advanced NSCLC - Patients who developed resistance to an EGFR-TKI due to any other phenotypic/histologic transformations (e.g., small-cell lung cancer, EMT) or other mutations (e.g., HER2, MET amplifications) at the index-date will be eligible for participation in this study as long as they have prior confirmed diagnosis of EGFR mutation-positive (all mutations) locally advanced or advanced NSCLC
Patients who have progressed on or after EGFR-TKI therapy (i.e., gefitinib, erlotinib or afatinib) within the patient selection period
Provision of written informed consent (patient consent should be within 6 weeks of NSCLC diagnosis, defined elsewhere as the Index Date)
Adult male or female subjects (according to age of majority/adulthood as defined by local regulations)
Patients diagnosed with de-novo EGFR T790M mutation-positive locally advanced or advanced NSCLC during the patient selection period. The de-novo T790M mutation can be alone or in combination with other mutations (e.g., L858R and T790M).
You may not be if
Enrollment in studies that prohibit any participation in this non-interventional study. These patients will be censored.
